Background. Delays detecting treatment failure and switching to second-line combination antiretroviral therapy (cART) are often observed in human immunodeficiency virus (HIV)-infected children of low-middleincome countries (LMIC).
Although virological failure is widely considered the criterion standard to detect treatment failure, clinical and immunologic parameters are often the only criteria available in LMIC [5, 6] . CD4 cell monitoring has been shown to be a poor predictor of virological failure in treatmentexperienced children [7] [8] [9] , particularly when severely immune-compromised [10] . Studies in LMIC have reported high rates of virological suppression in children up to 5-6 years after treatment initiation [11, 12] ; however, treatment failure rates of 10-34% were observed among children after 2-3 years of cART [13] [14] [15] [16] [17] [18] . Program reports suggest that only a small proportion of patients on treatment are receiving a second-line therapy, an estimated 4% of adults and 1-14% of children [16, [18] [19] [20] . Delays in detecting treatment failure and switching to second-line therapy lead to the development of HIV drug-resistance, compromising subsequent regimens [6, 21] . This is particularly relevant for children, due to the lack of pediatric formulations.
Randomized trials were conducted to evaluate the optimal first antiretroviral regimen for reducing the risk of treatment failure. Findings from the P1060 trial reported an increased risk of failure starting a nevirapine (NVP)-based cART in infants and young children [13, 22, 23] . This was not confirmed by the PENPACT1 trial, where no difference in clinical and virological outcomes were shown between non-nucleoside reverse-transcriptase inhibitors (NNRTI) and protease inhibitors (PI)-based regimens in older children [24] . Data to inform the most durable nucleoside reverse-transcriptase inhibitors (NRTI) backbone in the context of a triple therapy is still limited. Conflicting results were reported concern the use of abacavir (ABC) as first-line regimen: Green et al. suggested that abacavir (ABC) may be preferable to zidovudine (AZT) combination with lamivudine (3TC) [25] , while poorer early virological outcomes were recently observed in children starting ABC/ 3TC-based first-line regimens, compared to stavudine (d4T)/3TC [26, 27] . Identifying optimal regimens is particularly relevant for children with HIV/tuberculosis (TB) coinfection living in LMIC, where NVP is widely preferred to efavirenz (EFV) or a triple NRTI-based regimen, due to its better acceptability and relatively low cost [28] .
Drug substitution is often required to optimize antiretroviral treatment [19, 29] . Results from observational studies estimate a probability of cART discontinuation or modification ranging between 2.8% and 20% in adults of LMIC [19, [30] [31] [32] [33] [34] . A randomized study conducted in children shows a cART switching/discontinuation rate up to 29% [24] . Acute and chronic toxicity, drug intolerance, poor adherence, and treatment failure remain the major determinants of cART modification [35] [36] [37] [38] . Drug costs and/or being out of stock due to challenges in adequately forecasting and maintaining an effective supply chain have been cited as further reasons for cART discontinuation in LMIC [31, 33] .
The aim of this study is to estimate the rate and predictors of cART treatment failure in 2 pediatric cohorts from Mozambique and Uganda during a 5-year follow-up period, and to explore the rate of and factors associated with drug substitution.
METHODS

Setting and Study Design
We conducted a retrospective cohort study among children starting cART between January 2005 and December 2009 at the Beira Central Hospital (HCB) in Mozambique and the Nsambya Home Care (NHC) department of St. Raphael of St. Francis Hospital in Uganda. Two Italian nongovernmental organizations, Doctors with Africa Cuamm (Mozambique) and Associazione Casa Accoglienza alla Vita Padre Angelo (Uganda), partnered with these hospitals to provide pediatric HIV care.
Both programs provided HIV counseling and testing, cotrimoxazole prophylaxis, cART, laboratory investigations, and management of opportunistic infections. Infants and children under 18 months of age, known or suspected to be exposed to HIV, were diagnosed through HIV-1 DNA testing. Patients were considered eligible for cART according to WHO 2006 guidelines [39] .
Laboratory examinations including full blood count, liver function tests, creatinine, and CD4 count were required before starting cART, as well as a chest radiograph and acid-fast bacilli testing to exclude TB if suspected. In the absence of contraindications, written consent was collected when enrolling in the programme and before starting cART. Throughout the study, patients were switched to second-line cART when treatment failure was identified following WHO 2006 guidelines [39] .
The study was approved by the ethics committees of HCB and Nsambya Hospital and registered by the Uganda National Council for Science and Technology and by the Gabinete Do Director Gerar, Ministerio Da Saudè of HCB (Mozambique). Data Collection. In Mozambique, data were collected from clinical charts and paper registries and entered in the hospital's electronic patient database system. Similarly, in Uganda, routine clinical data were recorded in paper-based patient files and registries and entered into an electronic interface by trained staff.
Children were examined at least monthly during the first 6 months of cART and then every 3 months in Mozambique, while in Uganda monthly visits were maintained throughout the follow-up according to the project design. Weight and height were measured at every clinic visit. Full blood count, liver function tests, and glucose assays were performed every 6 months, and CD4 counts every 6-12 months. Adherence to cART was assessed at every follow-up visit and defined as "good" or "poor" if the self-reported number of doses was more or less than 95% of expected monthly number of doses. HIV-related clinical events were diagnosed with or without biological confirmation, depending on lab facilities available, while immunodeficiency was classified as mild, advanced, and severe according to the WHO 2006 thresholds [39] . For the treatment failure analysis, the period of follow-up was from cART initiation up to the treatment failure outcome, while follow-up was from treatment initiation to first cART drug substitution for drug-substitution analysis. For children without treatment failure or drug substitution, follow-up was censored at date of death, loss to follow-up (LTFU, defined as missing follow-up visits for more than 6 months), transferred to other clinic, confirmed HIVnegative or aged more than 18 years old, last CD4 measurement, or last anthropometric or adherence record, whichever occurred latest. Endpoint Definitions and Study Population. Drugsubstitution was defined as substitution of one or more drugs of the first antiretroviral regimen for any reason. Reasons for drug substitution were classified retrospectively from the inspection of what was reported by clinicians in patient's clinical charts. Clinical and immunological failure were defined according to the WHO 2006 criteria, using CD4 measurements and WHO disease stage from at least 24 weeks after cART initiation [39] . Treatment failure, when both clinical and immunological failures were observed, was considered to occur at the earliest of the two events.
For analysis of treatment failure, only children with at least 24 weeks of follow-up post-cART initiation were included to ensure sufficient time for treatment response.
For analysis of cART drug substitution, children who received an ABC component in their initial cART regimen were excluded, as first-line ABC treatment was systematically administered to children diagnosed with active TB and all patients initially on ABC were routinely switched to EFV once the TB infection cleared. Statistical Analyses. In this intent-to-treat analysis, all children were included from cART initiation, regardless of subsequent modifications. All analyses were conducted in R version 2 (R Development Core Team, Vienna, Austria) and Stata version 12.0 (Stata Corporation, College Station, TX).
For both treatment failure and drug-substitution analyses, frequency distributions and median and interquartile range (IQR) were used to describe baseline patient characteristics. Baseline characteristics of interest were gender, age at treatment initiation, body-mass index (BMI, weight[kg]/height 2 [m]) for age z-score, WHO disease stage, initial cART treatment regimen (also by most potent component), adherence to cART, CD4 count and percent, and immunodeficiency classification. All descriptive analyses were stratified by hospital. Differences in all key variables at baseline between these strata were determined using Pearson's χ 2 test for categorical variables, the t-test for difference in means for baseline BMI for age z-score, and the Wilcoxon rank-sum test for all other continuous variables.
Unadjusted Cox proportional hazards models were used to determine the odds of treatment failure and cART drug substitution. The following variables were considered in a multivariate adjusted Cox proportional hazards model of treatment failure: cART treatment regimen, age, adherence, gender, country of treatment, baseline disease stage, immunodeficiency status, and BMI for age z-score. The following variables were considered in a multivariate adjusted Cox proportional hazards model of cART drug substitution: cART treatment regimen, adherence, classification of immunodeficiency status, WHO disease stage, and age group. A backward-selection procedure was used to create these adjusted models, with a variable being included in the model if it resulted in an improvement in the model fit as defined by the Akaike Information Criterion (AIC).
RESULTS
Between January 2005 and December 2009, 1075
HIV-infected children less than 15 years old began cART in HCB and NHC. Two hundred thirteen (20%) children were excluded from the study due to missing data (Table 1) . Children excluded from both treatment-failure and drug-substitution analyses were more likely to be Ugandan (P < 0.01), female (P = 0.049), younger (P < 0.01) and enrolled and starting cART later (P < 0.01 and < 0.01, respectively) than children included in the study.
Treatment Failure Analyses
Among 862 children eligible for analysis, 740 children (492 from Mozambique and 248 from Uganda) with at least 24 weeks of follow-up were included for a total of 1088.5 person/years of follow-up. At the time of data collection, 24/740 (3.24%) children died, 68 (9.19%) were LTFU, 7 (0.95%) were transferred to another clinic, and 1 (0.14%) was confirmed HIV-negative. A total of 218 treatment failure events (29%; 95% CI 26-33) occurred, with a crude incidence rate of 20.0 events per 100 personyears (95% CI 17.5-22.9). Median time to treatment HIV and Treatment Failure in Children 41 failure was 379 days (IQR 229-649). Immunological failure alone occurred in 100 (46%) children, while clinical failure alone was found in 116/218 (53%) cases. Two children (1%) had concomitant clinical and immunological failure. Baseline characteristics are shown in Table 2 .
The adjusted Cox proportional hazards model of treatment failure with the lowest AIC included age, treatment type, and baseline disease stage. Incidence rates and crude and adjusted relative hazards from the model are shown in Table 3 .
Patients with TB and those with other WHO stage 4 defining diseases were significantly more likely to experience treatment failure (Hazard Ratio [HR] 2.27, 95% CI 1.5-3.4, P < 0.01 and HR 1.57, 95% CI 1.02-2.4, P = 0.04, respectively) compared to children with WHO stage 3 disease without TB. As expected, starting cART with an unconventional regimen (not containing an NRTI backbone in combination with EFV, NVP, lopinavir/ritonavir (LPV/r), or ABC) was also significantly associated with risk of treatment failure (HR 3,37, 95% CI 1.12-11.89, P = 0.03).
Drug Substitution Analysis. Among 862 eligible children, 4 with unknown ART regimen and 89 who received ABC in their initial cART regimen were excluded from the cART drug-substitution analysis. The remaining 769 children had an overall follow-up of 1499 person/years. Baseline characteristics of this cohort are provided in Supplementary  Table 1 (see online Supplementary Material for this table) .
Throughout the study period, 202 (26%, 95% CI 23-30) patients substituted treatment, with median time to substitution of 9.69 months (IQR 25.82). Overall incidence of substitution was 15.4 events per 100 person-years (95% CI 13.4-17.7). Reported reasons for substitution included any toxicity (37, 18.3%), of which 3 were d4 T toxicity (1.5%), 25 (12.4%) AZT toxicity, and 9 (4.5%) NVP toxicity, clinical and immunological failure (9, 4.5%), drug availability (35, 17 .3%), drug interaction (1, 0.5%), provider preference for a better option (32, 15 .8%), simplification associated with nonadherence (4, 2%), caregiver health problem (1, 0.5%), and TB drugs interaction (52, 25.7%). Among the 9 patients with drug substitution for clinical or immunological failure, median time to Drug substitution was more likely among patients starting 3TC-AZT-NVP (adjusted HR 3.29, 95% CI 2.27-4.76, P < 0.01), 3TC-d4T-EFV (adjusted HR 3.22, 95% CI 2.02-5.13, P < 0.01), or 3TC + AZT + EFV (adjusted HR 1.74, 95% CI 1.03-2.95, P = 0.037) compared to 3TC-d4T-NVP.
Mildly immunosuppressed patients (adjusted HR 2.23, 95% CI 1.24-4.02, P < 0.01), infants (adjusted HR 2.74, 95% CI 1.54-4.90, P < 0.01), children with TB (adjusted HR 3.38, 95% CI 2.28-5.01, P < 0.01) and those with good treatment adherence before drug substitution (adjusted HR 0.53, 95% CI 0.37-0.77, P < 0.01) were also more likely to substitute cART. Incidence rates and crude and adjusted relative hazards from the model are shown in Supplementary  Table 2 (see online Supplementary Material for this table) .
DISCUSSION
In this study, a notable proportion (29%) of HIV-positive children experienced clinical and/or immunological cART failure, with a crude incidence rate of 20.0 events per 100 person-years. Our findings appear to be in line with evidence from the literature referring to immunological failure [16] [17] [18] . Considering that virological failure tends to precede clinical and immunological failure, this figure could underestimate a greater impact of virological failure. WHO clinical stage 4 and TB co-infection at cART initiation were significantly associated with treatment failure. Poor clinical status has been observed to negatively affect treatment response; in particular, malnutrition and chronic diarrhea independently increase the risk of treatment failure as much as baseline low immunity, high viral load (VL), and younger age [15] [16] [17] . As suggested by Hermans et al. [40, 41] , TB co-infection may impair immune recovery after cART initiation in adults. In addition, poor adherence may occur as a result of high pill burden, and interaction with rifampicin may affect the bioavailability of HIV drugs, particularly for NVP and LPV/r [42] . Development of better options for TB co-treatment appears to be critical to prolong effectiveness of first-line regimens.
As expected, unconventional regimens were associated with treatment failure compared to triple cART [37] . Treatment failure was not different between PI-based and NNRTI-based regimens; however, the validity of this finding may be questionable considering that only a few children were receiving a PI-based regimen at the time of the study. Few randomized trials investigated the most effective first-line cART regimen in HIV-positive children. The P1060 trial [13, 23] showed an increased risk of virological failure in children (<3 years) on NPV-based cART, regardless of prevention of mother to child transmission (PMTCT) exposure; however, this was not confirmed by the PENPACT trial conducted in older children of high-income countries [24] . Due to the nature of our cohort's age and lack of reliable PMTCT exposure data, our observational retrospective findings are not comparable to those from either controlled trial.
Reasons for drug substitution were assessed to explore whether this was in response to treatment failure. However, over a 5-year period, only 4% of 202 patients who substituted cART switched to a second-line regimen due to treatment failure. Drug substitution occurred after a median time of 26.65 months, indicating a significant delay in switching to second-line despite the high rate of failure retrospectively observed in the cohort. Although reasons for substitution may have been misclassified, the small number of children switching due to treatment failure implies that a prolonged exposure to failing regimens may have occurred in these two settings. Several studies reported a low proportion of children on second-line cART in LMIC [19, 20] . Our switch rate appears even lower than those observed by Davies et al. [16] and by 2 other observational studies showing that around 14% children switched to second-line due to clinical and/or immunological failure [17, 18] . Reasons explaining the alarming gap between a recognized clinical and/or immunological failure and the initiation of a second-line cART were not well identified. In our program, we hypothesize that limited availability and costs of second-line drugs may be major barriers to second-line therapy. Furthermore, the tradeoff that clinicians are facing when considering the limited options for children failing first-line and the risk of maintaining them on a failing regimen can be very challenging and may result in further delays in switching to second-line cART. Underdiagnosis of treatment failure may also have contributed to the low rate of switching observed, as reasons for switching were collected retrospectively based on clinician report, leading to possible misclassification.
Determining when to switch to second-line cART is a critical decision in settings where virological monitoring is not available. Although evidence shows that VL is not essential to identify treatment failure [34] , using clinical and immunological parameters leads to delays in switching to second-line therapy [17] , resulting in longer exposure to failing regimens, which contributes to development of drug-resistant HIV strains [6] . In our study, reasons for delays to cART switching were not completely clarified; in particular, we were unable to understand if clinicians did not switch cART in children with recognized treatment failure or if clinical/immunological criteria were too complicated to recognize treatment failure. Earlier cART initiation and VL monitoring are currently recommended by WHO 2013 consolidated guidelines [3] . Based on our data, advanced disease and TB co-infection should be considered as warning signals requiring closer follow-up and counseling to improve treatment outcomes and prolong duration of first line therapy. Adherence to cART was found to be a poor indicator of treatment failure, maybe due to the low accuracy of self-reporting adherence monitoring.
About 26% (203/769) of patients substituted treatment with an overall incidence rate of 13.5 events per 100 person years and 95% of these were for causes other than treatment failure. This figure is consistent with previous HIV and Treatment Failure in Children 45 observational studies among HIV-positive children [17, 24, 40] living in LMIC. Toxicity/intolerance was one of the main reasons reported for substitution (18.3%), mostly related to AZT toxicity (12.4%), as reported in other studies [17, 38, 41] . Due to high prevalence of HIV/TB co-infection (88/769, 11.4%), drug interaction in TB/HIV co-treatment (25.7%) was another major reason to substitute drugs. Drug availability (17.3%) was another considerable reason, reflecting the importance of ensuring adequate and continuous supply of cART in settings where drug costs are still a major barrier for PLWH. Reasons for drug substitution were not classified prospectively but assessed from inspection of patient clinical charts, potentially leading to inaccurate classifications.
Higher rates of drug substitution were observed among children starting AZT-containing or EFV-based regimens. Increased drug substitution while on AZT is often the result of AZT-related anemia as well described previously [23, 31, 36] . AZT toxicity was more prevalent among the Mozambique cohort, where children were younger and malnutrition and/or more advanced WHO disease stages were observed, suggesting that AZT anemia may have been exacerbated. Despite the lack of more robust evidence, our findings suggest that AZT may not be the preferred NRTI to be used in these settings, particularly in younger children.
Further description of EFV substitution was not possible in this dataset due to the limited number of children receiving this drug, and we could not rule out specific EFV-related toxicity.
As previously mentioned, our results may be confounded by country-specific differences. Mozambique patients were younger, had a more advanced WHO stage, and a lower BMI z-score at cART initiation. These differences may reflect clinicians' preference in first-line treatment choice, accounting for the wider use of AZT and EFV in Uganda as much as for the increased choice of NVP-based regimen observed in children from Mozambique. Country-specific differences may potentially confound the relationships seen between cART regimen and treatment failure and drug substitution. In terms of follow-up visits, the Ugandan children were followed up much more frequently (monthly) than those in Mozambique (every 3 months). This difference between program performances may have provided further confounders, potentially influencing the trends observed in older children at lower risk of failure and the higher rate of drug substitution observed in infants.
In conclusion, our data reinforce the need for simplification of more effective clinical and immunological criteria for prompt recognition of cART treatment failure. Children presenting with advanced disease and TB co-infection should be targeted for closer and more sensitive monitoring of treatment response. This should be matched with a regular provision of appropriate antiretrovirals and with optimization of first-line drugs and treatment sequencing. Supply of new pediatric formulations for second-line regimens and drug optimization should be considered as critical milestones to allow scaling up of early cART and reduction of treatment failure in children.
